ERDAFITINIB

Erdafitinib is a tyrosine kinase inhibitor targeting FGFR14, used in metastatic urothelial carcinoma with FGFR alterations. It blocks proliferative signaling and tumor growth. Side effects include hyperphosphatemia, stomatitis, ocular toxicity, fatigue, diarrhea, and nail disorders. Only GMP materials will be supplied, logistics all according to GDP.

Category:

Product Description


Mechanism of Action

ERDAFITINIB demonstrates a highdimensional biochemical activity framework integrating catalyticdomain modulation, multiaxis signalling interference, mitochondrialnetwork recalibration, redoxequilibrium restructuring, ionflux redistribution, membranepotential modulation, cytoskeletalarchitecture remodelling and transcriptionfactor circuit reprogramming. The compounds molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotidebinding pockets, redoxbuffer matrices and polymeric scaffolding complexesenabling influence across metabolic, genomic, structural and electrophysiological systems.

ERDAFITINIB may alter phosphorylationflow geometry across ERK, MAPK, JNK, p38 and PI3KAKT axes; reconfigure Gprotein signalstate logic; redistribute Ca²⁺ microdomains; adjust IP/DAG signalling topology; and recalibrate cAMPPKA amplitude. Mitochondrial effects include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, membranepotential polarity shifting, and ERmitochondria stresssignal crosstalk integration.

HighPrecision

  • Kinomescale interference mapping & catalyticcascade modelling
  • Highresolution molecular docking & conformationaltransition prediction
  • UPR/ERstress, mitophagy & autophagicflux regulatory modelling
  • Multiomics network reconstruction: RNAseq, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletal tensionmapping & polymerturnover analytics
  • Advanced cellfate pathway modelling (apoptosis, necroptosis, ferroptosis, parthanatos)
  • AIdriven SAR/QSAR predictive compoundperformance optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS escalation & antioxidantbuffer collapse
  • Mitochondrial fragmentation or ETCaxis suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionic-flux destabilisation
  • Cytoskeletal depolymerisation & membrane-integrity loss
  • Inflammatory hyperactivation (NF-κB, STAT, IRF signalling clusters)
  • Activation of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation/acetylation instability

For expert not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C25H30N6O2

Molecular Weight

446.5 g/mol

CAS Number

1346242-81-6

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

<1 mg/mL

Purity

Purity information is available upon request (COA).

Synonym

Erdafitinib; 1346242-81-6; Balversa; 890E37NHMV; DTXSID001027936

IUPAC/Chemical Name

N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine

InChl Key

OLAHOMJCDNXHFI-UHFFFAOYSA-N

InChl Code

InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3

References

https://pubchem.ncbi.nlm.nih.gov/compound/67462786;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download